Fosfomycin intravenous - Zavante Therapeutics

Drug Profile

Fosfomycin intravenous - Zavante Therapeutics

Alternative Names: Fosfomycin disodium; ZTI-01

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Zavante Therapeutics
  • Developer National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Urinary tract infections
  • Phase II Intra-abdominal infections; Skin and soft tissue infections
  • Phase I Pseudomonal infections

Most Recent Events

  • 19 Jan 2017 Zavante Therapeutics completes enrolment in the Phase-II/III ZEUS clinical trial in Urinary tract infections (In the elderly, In adults) in Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Georgia, Hungary, Lithuania, Latvia, Poland, Romania, Russia, Slovakia, Ukraine (IV) (NCT02753946)
  • 15 Jul 2016 Phase-II/III clinical trials in Urinary tract infections (In adults, In the elderly) in Latvia, Slovakia, Greece (IV)
  • 14 Apr 2016 Zavante Pharmaceuticals announces intention to submit NDA to US FDA in Second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top